[Ghrelin-related drugs: clinical perspectives].
Shimatsu
Akira
A
National Hospital Organization, Kyoto Medical Center, Clinical Research Institute.
D001552:Benzazepines; D017321:Clinical Trials, Phase I as Topic; D004151:Dipeptides; D015195:Drug Design; D004393:Dwarfism, Pituitary / Q000188:drug therapy; D005021:Ethylamines; D001068:Feeding and Eating Disorders / Q000188:drug therapy; D054439:Ghrelin; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D045823:Ileus / Q000188:drug therapy; D007211:Indoles; D009842:Oligopeptides; D036361:Peptide Hormones / Q000494:pharmacology / Q000627:therapeutic use; D012893:Sleep Wake Disorders / Q000188:drug therapy; D013141:Spiro Compounds; D013268:Stimulation, Chemical; D013777:Tetrazoles
D001552:Benzazepines; D004151:Dipeptides; D005021:Ethylamines; D054439:Ghrelin; D007211:Indoles; D009842:Oligopeptides; D036361:Peptide Hormones; C443685:SM 130686; D013141:Spiro Compounds; D013777:Tetrazoles; C086184:hexarelin; C081455:L 692429; C041048:growth hormone releasing hexapeptide; D013006:Growth Hormone; C091874:growth hormone-releasing peptide-2; C120631:tabimorelin; C094817:ibutamoren mesylate; C114611:ipamorelin